A Fee Line, a Three-Turn Reset and a Wider Normalizer Gap: Upgrading Welltower to Outperform

Results vs. Consensus

Q3 2026 Scorecard

A note on the GAAP line. In July we declined to score GAAP earnings because two data feeds disagreed by fourteen percent. This quarter every estimate we found sat between $0.62 and $0.65, and the $0.54 actual misses all of them. The miss is not operational. It comes from $124.7M of other expenses, $33.5M of asset impairments and a $30.7M loss from unconsolidated entities, partly offset by a $114.7M gain on dispositions. We score it as a miss and we do not think it should drive the stock. The early headlines that led with it are a different matter, which we return to under Market Reaction.

Year-Over-Year Comparison

Sequential Comparison

Basis note: the same-store occupancy, margin and RevPOR figures are drawn from this quarter's five-period series, which restates prior quarters onto the new 1,052-property pool. On its own 980-property pool the company reported 89.4% occupancy and a 32.1% margin for Q2. We use the restated series for every sequential comparison in this note.

Segment Performance

Same-Store NOI by Segment

Annualized In-Place NOI by Segment

Seniors Housing Operating

The segment is the company: 70.0% of annualized in-place NOI, 73.7% of same-store NOI and 83.8% of pro rata revenues. Total-portfolio segment NOI was $904.3M against $573.1M a year ago, on 1,810 properties and 176,652 units against 1,199 and 131,792. Same-store NOI grew 21.0%, up from 20.5% in Q2, which extends the run of quarters above twenty percent to sixteen.

"This marks the 16th consecutive quarter or 4 full years of compounding growth in which the SHOP same-store NOI grew over 20%." — John Burkart, Chief Operating Officer

Assessment: Year over year, everything in this table improved, and the margin line is now three points above where it stood twelve months ago on the same pool. The one cell that deserves a second look is sequential RevPOR, flat at $6,066 against $6,074 in the quarter that added 120bps of occupancy. In this business most in-place rent increases land in January, so a flat summer is normal. It also means the street-rate strength management described is not yet visible in the pool average. We expect it to show up in the January reset, and that is the place to test it.

Seniors Housing Triple-net

Same-store NOI grew 4.2%, slower than Q2's 5.2%, with trailing twelve-month EBITDAR coverage of 1.22x against 1.23x and EBITDARM coverage of 1.46x. Guidance for the segment was held at 3.5%-4.5%. The property count fell to 386 from 424 and in-place NOI to $603.6M from $623.9M, consistent with the triple-net-to-operating conversions that produced the $2.5M straight-line write-off in normalizing items. The United Kingdom holds $386.4M of the segment's in-place NOI.

Assessment: A quiet segment that is shrinking by design as leases convert to operating structures. Coverage of 1.22x is adequate rather than comfortable and remains the place a tenant credit problem would surface first.

Outpatient Medical

Down to 97 operating properties from 121 and $115.0M of in-place NOI, or 2.3% of the total. The company sold 25 Outpatient Medical properties in the quarter for $139M, taking year-to-date Outpatient Medical dispositions to $2.06B across 99 properties. Same-store NOI grew 2.4% on 91 properties at 96.9% total occupancy. Kelsey-Seybold is now 67.5% of the segment's rental income.

Assessment: The wind-down is effectively complete as a portfolio matter. The release does not say whether the last eight properties in the $7.2 billion transaction have closed, and the call described the disposition total as including "the medical office transaction that we talked about last year that is obviously closed in tranches." What remains is a small, concentrated, health-system-affiliated portfolio that no longer moves the consolidated number.

Skilled Nursing

Same-store NOI grew 2.8% on 249 properties with EBITDAR coverage of 1.32x, up from 1.30x. The segment grew to 15.8% of in-place NOI from 14.9% on $857M of third-quarter acquisitions across 44 properties and $2.47B year to date. The payor mix is 23.6% private, 49.9% Medicaid and 26.5% Medicare, and Avir Health Group, a triple-net tenant at 7.3% of total in-place NOI, is the company's third-largest partner.

"1 new trend we are starting to see is seeing HUD for the first time impose single borrower limits on how much capital they will finance for any particular person through HUD." — Nikhil Chaudhri, Chief Investment Officer

Assessment: Management describes a new source of motivated sellers in a segment it once called a bad business, at rent yields "always been around 9%." The yield is attractive and the track record with former Integra operators is real. But this is the one segment growing its share of NOI that carries Medicaid reimbursement risk, and it now accounts for nearly one dollar in six of in-place NOI.

Geographic Mix

Occupancy and margin are for the total SHO operational portfolio as restated in this quarter's supplement; the company changed the margin basis this quarter, so the Q2 column is drawn from the restated series rather than July's report.

Assessment: The United Kingdom improved, with margin up 90bps sequentially to 25.3%, but it remains the part of the portfolio furthest from the 90% occupancy level at which management says pricing takes over. The United States moved the other way: total-portfolio margin fell 80bps sequentially to 30.4% as 34 net new properties came in during a quarter whose seniors housing acquisitions averaged 66% occupancy. That is the acquisition drag we flagged in July showing up in the largest country.

Key Topics & Management Commentary

Overall Management Tone: Confident and more expansive than in July, with a larger share of the prepared remarks given to a deteriorating macro backdrop and to a pricing story presented as a change of regime rather than a good quarter. The combative edge of the summer call softened into instruction, and Q&A was long on strategy and short on challenge. Management was least forthcoming on what moved the NAREIT line: the guidance walk covered only normalized FFO, and the operator restructuring behind part of the quarter's $124.7M of other expenses went unmentioned.

1. The NAREIT Line Went the Other Way

In April we called NAREIT FFO guidance the single most important disclosure to track. In July it moved up for the first time, and we scored that as half a resolution because a discrete $71.3M tax release did most of the work. This quarter it moved down. The NAREIT range went to $6.07-$6.13 from $6.21-$6.29, a $6.10 midpoint, while normalized went to $6.47-$6.53 from $6.36-$6.44. The guidance reconciliation now carries $298M of net normalizing items for the year, up from $111M, and $298.3M has already been booked through September.

In dollars, the midpoint of NAREIT FFO guidance fell $73.5M and normalized rose $113.5M. The $187M increase in guided normalizers is larger than the entire normalized raise. Put differently: had the quarter's excluded costs been treated as ordinary expenses, the full-year guide would have been cut.

"Our normalized FFO guidance represents a $0.10 increase at the midpoint from our prior normalized FFO range. This increase is comprised of a $0.03 increase from senior housing operating NOI, a $0.055 increase from investment and financing activity, and a 1.5-cent increase from FX and income tax. Slightly offset by higher expected G&A." — Tim McHugh, Chief Financial Officer

That bridge is accurate and it is for the normalized line only. In July we wrote that the normalized guide was structurally conservative, that the NAREIT guide was the honest one, and that the gap would likely re-widen in the second half. We were right about the gap and wrong about the honesty: the July NAREIT guide also assumed no second-half transaction costs, because guidance only includes normalizing items already disclosed. The new $6.10 makes the same assumption for the fourth quarter, while $7.7 billion of investment across 50 transactions is still to close.

Assessment: This is the substance half of our earnings-quality concern resolving against the company. The disclosure is complete and the reconciliation is honest. But the stock is valued on the line that excludes roughly $0.50 a share a year of recurring deal and legal costs, and for 2026 the entire guidance increase has come from that exclusion. Bear-2 moves to Materializing.

2. Twenty-One Percent, and the Sixteenth Straight Quarter

SHO same-store NOI grew 21.0%, against 20.5% in Q2 and 22.1% in Q1 on their own pools. Total portfolio same-store NOI grew 15.8%. Full-year SHO guidance went to 20.25%-21.75% from 18.5%-21.5%, lifting the midpoint to 21.0% from 20.0%, and the blended range went to 15.0%-16.25% from 13.75%-16.00%.

"Turning back to the quarter, our total portfolio same store net operating income increased 16%. Second highest level of growth achieved in our recorded history." — Shankh Mitra, Chief Executive Officer

The components behind the SHO range were unchanged on revenue (9.3% growth, 5.1% RevPOR, +350bps occupancy) and improved on cost: expense growth is now guided at 4.6% against 5.0% in July, equal to ExpPOR growth of about 0.6% against roughly 1%.

Assessment: In July only the low end of the range moved; this time the high end moved too, by 25bps. That is the first ceiling increase since we initiated coverage in April. Three quarters at or above 20.5% make the mid-teens downgrade trigger a distant risk rather than a live one.

3. The Handoff From Occupancy to Rate

The central message of the call was that pricing is taking over from occupancy as the engine of revenue growth, earlier and more strongly than the company expected. Same-store RevPOR growth accelerated for a third consecutive quarter to 5.3%. Management broke it down further than before.

"However, as communities are filling up, the deliberate and methodical handover from occupancy to pricing as the driver of revenue growth is taking place under the surface." — Shankh Mitra, Chief Executive Officer

"If we zoom into the U.S., occupancy crossed 90%, the portfolio achieved RevPAR growth of 5.5%. If you further zoom into a traditional senior living business, the same number was 5.8%." — Shankh Mitra, Chief Executive Officer

Communities above 90% occupancy, two-thirds of the portfolio, are producing RevPOR growth above 6% and NOI growth above 21%. Management attributed the acceleration to street rates, since in-place increases are mostly set in January, and restated a self-imposed ceiling of roughly high-single-digit increases for existing residents.

Assessment: This is the most important strategic development of the quarter and the strongest support for the upgrade. Pricing-led growth carries higher flow-through than occupancy-led growth, and it does not run out at 95% occupancy the way the occupancy story does. The caveat is the one in the segment table: sequential same-store RevPOR was flat in Q3. The test of the street-rate claim is the January rent cycle, and we will grade it there.

4. Occupancy Crosses Ninety

Same-store occupancy averaged 90.2%, up 320bps year over year and 120bps sequentially. July asked whether the summer leasing season would confirm the full-year guide of +350bps. The sequential gain did; the year-over-year figure, +320bps, still sits below a guide that was maintained rather than raised.

"Against a backdrop of growing macro uncertainty, the demand for luxury senior living remained resilient, during the summer months, with a 120 basis points of average occupancy increase from second quarter. This gain exceeded the sequential occupancy increase recorded during the same period last year." — Shankh Mitra, Chief Executive Officer

Management also gave an early read on 2027: "Unless the strong sequential tailwind we experienced in Q2 and Q3 subside, we should be in a position to deliver another year of favorable occupancy growth next year."

Assessment: The peak-season test passed, and the 2027 comment is an early forward signal on occupancy beyond the current year. The full-year +350bps guide was left untouched against +320bps in the quarter, which is consistent with the company's habit of moving guidance only once the outcome is banked.

5. Flow-Through at a Post-COVID High

Incremental flow-through reached 66%, from 65% in Q2 and 64% in Q1. Compensation per occupied room grew 0.9% and total ExpPOR 0.8%; in Canada ExpPOR was essentially flat.

"Notably, the flow through margin for the quarter was 66%, a post COVID high watermark for the company. While operator leverage provides meaningful flow-through, but the rental rate growth is a more powerful driver. As incremental revenue carries essentially no associated cost." — John Burkart, Chief Operating Officer

The cohort that tells you where this goes is the 95%-plus-occupied group, which management put at about 35% of the properties in the same-store pool, and where the RevPOR-to-ExpPOR spread is "comparable to, if not greater than" the rest of the portfolio.

Assessment: July's 70%-plus marker at 95% occupancy applies to a cohort large enough to be visible in the consolidated number. The cyclical labor caveat we raised in July still applies, but the expense guide was cut this quarter rather than raised, which is the direction that matters.

6. The Integration Drag Widened

Total-portfolio SHO occupancy was 88.3% against same-store 90.2%, a 190bps gap against 180bps in July on the figures reported then. The non-same-store pool, newly disclosed as its own table, held 758 properties and 61,700 units at 84.3% occupancy and a 27.2% margin, little changed from 84.5% and 27.4% in Q2. In the United States the total-portfolio margin fell to 30.4% from 31.2%.

"If you strip those out and look at the assets that have been in the pool, for kind of like-for-like periods, get closer to 90 basis points of sequential occupancy increase." — Tim McHugh, Chief Financial Officer

Management also pointed to operator changes: "Everything we are buying, we are effectively changing operators, so that disruption is also there."

Assessment: The drag is the arithmetic of buying 66%-occupied buildings, and the like-for-like figure of about 90bps of sequential gain says the assets already owned are filling. We accept the explanation. It also means the reported total-portfolio numbers will keep trailing the same-store numbers for as long as the acquisition pace runs at this level. Because acquisitions enter the same-store pool only after five full quarters, that is all of 2027 even if buying stopped today.

7. $21 Billion, 196 Deals, and a 5.3% Going-In Yield

Year-to-date investment activity closed or under contract reached $21.0 billion: $13.3 billion completed through September and $7.7 billion closed or under contract since, across 50 transactions. In the quarter the company completed $3.87 billion of acquisitions and loan funding at a 5.3% yield and $484M of dispositions and loan repayments at 5.2%. Year to date the two sides are 6.2% and 7.0%.

"These assets have an average age of 4 years, an average size of over 160 units, and are 66% occupied. These communities have a blended RevPOR in excess of more than $10 thousand per month." — Nikhil Chaudhri, Chief Investment Officer

The quarter's seniors housing purchases were bought at "an approximately 10% to 15% discount for replacement cost," narrower than the roughly 20% described in July. Of the pending $7.7 billion, 85% was sourced off-market and more than half involves sellers taking part of their proceeds in Welltower operating partnership units. The chief executive said the company can underwrite "untrended acquisitions today, that is in the high-7% to low-8% range" after post-closing improvement.

Assessment: Our downgrade trigger on the recycling spread did not fire: the quarter's acquisitions out-yielded its dispositions by 10bps, after a 10bps shortfall in Q2. But both sides fell, the going-in yield on acquisitions is down from 7.6% in Q1 to 5.3%, and the discount to replacement cost narrowed. The bull case on these assets rests on a stabilized yield of high-7% to low-8% that is stated but not disclosed per deal. We extend that trust because the same-store results keep validating it.

8. The Equity Is the Funding Currency

The company raised $4.4 billion in the quarter: $3.1 billion from share issuance and operating partnership units, $480M of capital recycling and $835M from its first Canadian unsecured issuance since 2019.

"During the third quarter, we raised $4.4 billion of capital, comprised of $3.1 billion from share issuance and OP unit funding, $480 million of capital recycling, and $835 million from our return to the Canadian unsecured market." — Tim McHugh, Chief Financial Officer

The quarterly filing adds the detail the call did not. The $7.5 billion at-the-market programme filed in late July had $4.86 billion of capacity left at September 30, so about $2.64 billion was drawn in roughly two months. Year-to-date at-the-market sales were 34.6 million shares for $7.56 billion at an average $218.07, and another 1.62 million shares were sold in October. Average diluted shares were 754.9 million, up 10.1% year over year; the guidance now implies about 747 million for the year, up from 741 million in July, and roughly 769 million in the fourth quarter.

Assessment: At 35x, the stock's normalized FFO yield is 2.9% against a 5.3% going-in yield on acquisitions, so issuing equity to buy assets remains accretive on paper. The cushion has narrowed: in July it was 2.6% against 6.1%. That spread is the economic engine of the per-share growth story, and both higher rates and a lower share price compress it.

9. A Fee Line, at Last

The company combined its earnings release and supplemental into a single document, and the new version includes a capital-light section: $10.2M of capital-light fees in the quarter, and $40.9M annualized on the net asset value page. The equity fund ($2.5 billion, 2025 vintage) and debt fund ($750M, 2026 vintage) are listed with their terms. Proportional income from unconsolidated management company investments rose to $21.4M from $17.9M in Q2.

"So, you know, in the capital-light business, we added some additional disclosure in our supplemental. And you will see we expect that the revenues from that business should continue to go up." — Nikhil Chaudhri, Chief Investment Officer

Management said a subsequent equity fund is being raised and that data science licensing partnerships are in discussion "with many groups." The disclosure overhaul also added ExpPOR and a non-same-store table, both of which analysts thanked the company for on the call.

Assessment: We said a disclosed fee line would move us to Outperform, and in July we wrote that we meant it. It is here. Annualized, it is 0.8% of the normalized FFO guide, so its value to the thesis is evidential: the businesses exist and will now be reported. We are honouring the trigger as written and are not pretending it changes the earnings power of the company.

10. HC-One and the U.K. Competition File

The quarter's other expenses were attributed in part to legal fees "related to the HC-One Group operator restructuring." The quarterly filing says Welltower bought HC-One, the operator of 282 U.K. seniors housing properties, in October 2025, and has since moved management of 89 of them to other operators. Neither the restructuring nor its cost was mentioned on the call.

The regulatory side has a public record we had not sized in either prior note. In January the U.K. competition authority opened a review of four care-home acquisitions completed in October 2025: 275 homes managed by Barchester, 279 by HC-One, 70 by Aria and Asprey, and 25 by Danforth. In May it found a realistic prospect of reduced local competition in 30 areas, and provisionally accepted Welltower's offer to sell ten named homes to pre-approved buyers and move four others to new operators.

Assessment: For two quarters we called U.K. and Canadian regulation the largest unpriced tail in the portfolio. On the record available, the U.K. tail has a size, and it is small: about fourteen homes out of 649. Bear-4 stays Contained. What remains unsized is the restructuring cost, which sits inside the excluded line where it does not reach the earnings the stock trades on.

11. The Macro Turned, and Management Leaned In

The chief investment officer opened with an unusually blunt macro summary: a September rate increase from the Federal Reserve, the 10-year Treasury at its highest since 2002, oil above $100 and rising private-credit and commercial mortgage delinquencies. He tied it directly to supply of assets.

"After roughly $8 billion of U.S. senior housing debt comes due in 2026, Annual maturities step up further, in 2027 and 2028. To between $10 billion and $12 billion." — Nikhil Chaudhri, Chief Investment Officer

"When financing markets turn volatile, sellers stop asking who will pay the most on paper. They ask who will actually close." — Nikhil Chaudhri, Chief Investment Officer

The same segment closed the Genesis Healthcare relationship: more than $130M of senior secured term loans were repaid in full after its bankruptcy, taking the lifetime unlevered IRR on that exposure to 9%. "I will be candid, A sub-10% return is nothing to celebrate."

Assessment: Higher rates cut both ways for this company, and the call presented only one side. They produce motivated sellers, which the pipeline confirms. They also raise the discount rate on a 35x equity, raise the cost of the 20.1% of debt that floats, and make the 2027 maturity year, $3.23 billion or 16.5% of debt, more expensive to refinance. The sector-wide sell-off on the reaction day is the market pricing the second side.

Guidance & Outlook

The normalized bridge from FY2025's $5.29 to the new $6.50 midpoint now reads: $0.67 from SHO NOI, $0.02 from Outpatient Medical and triple-net, $0.505 from investment and financing activity, $0.035 from income taxes and other, less $0.02 of G&A. Roughly 55% of the year's growth is organic seniors housing NOI and 42% is external investment. Management described the $6.50 midpoint as 22.9% growth, "now ahead of the full-year growth we delivered in 2025."

The disposition guide rose by about three-quarters to $1.9 billion over the next twelve months at a 6.5% blended yield, including $328M of expected loan repayments. That range likely includes the 30 communities Brookdale agreed this month to buy from Welltower for $290M; management called the deal "a win-win transaction" and said it was "happy with the price we got."

Implied fourth quarter: The guidance midpoints leave $1,351M of normalized FFO and $1,351M of NAREIT FFO for the fourth quarter. They are the same number, because the guide assumes no fourth-quarter normalizing items. On roughly 769 million implied shares that is about $1.76 a share on both measures, up 5% from Q3's normalized $1.67 and 21% from the $1.45 of Q4 2025.

Street at: The one full-year estimate we could find entering the print was $6.43, about 1% below the new $6.50 midpoint; we could not confirm it against a second estimate. The quarterly consensus of $1.64 was beaten by three cents.

Guidance style: Unchanged. Guidance includes only announced transactions and only disclosed normalizers, which has produced a normalized raise every quarter this year and, in the same construction, a NAREIT line that is cut whenever transaction costs arrive. The low end of the normalized range carries the information; the NAREIT midpoint for Q4 is a ceiling rather than a forecast.

Analyst Q&A Highlights

Where the Pricing Is Coming From

The question went to the heart of the call's message: how large the pricing opportunity is and how management measures it at the unit level. The answer separated the two components of rent growth and located the change in the one that is not set annually. Because in-place increases are mostly applied in January and are capped by policy, an acceleration during the year can only come from new-resident rates.

Q: "Shankh, how are you thinking about the magnitude of the pricing power opportunity for the portfolio? And then what metrics do you focus on to understand pricing power for an individual unit?"
— Nick Joseph, Citi

A: "So if ECRI remains relatively same, you get most of your ECRI at the beginning of the year. And only thing that is changed is street rates. So we are seeing meaningfully enhanced street rates."
— Shankh Mitra, Chief Executive Officer

Assessment: A precise, checkable mechanism, and the most bullish disclosure of the call. It did not come with a number: no street-rate growth figure was given, and the magnitude question went unanswered. The January rent cycle will show whether higher street rates have lifted the base that existing-resident increases compound from.

The Non-Same-Store Pool, Like for Like

A follow-up to July's most useful exchange. The new non-same-store table shows occupancy and margin lagging, and the question asked how those assets are actually performing and when the U.K. and Canadian purchases join the same-store pool. Management separated recently delivered and recently bought assets from the rest of the pool and said the remainder is tracking the same-store portfolio.

Q: "I was hoping to hear how the performance of the non same store pool is in SHOP. And just wondering, you know, because the metrics, I know it is helpful you guys give those metrics, in the supplemental. But they are kind of lagging on occupancy, margin growth."
— Nicholas Yulico, Scotiabank

A: "But those assets are performing well, and we think there is obviously significantly more upside over the next few years as you lease up those assets and then get into sort of that trend where you get pricing as a bigger opportunity for growth."
— Shankh Mitra, Chief Executive Officer

Assessment: The like-for-like figure of roughly 90bps of sequential occupancy gain is the useful part, and it is consistent with the pool being a lease-up line rather than a problem cohort. The answer on the U.K. and Canada was optimism about 2027 rather than data. Those portfolios enter the same-store numbers next year, and that is when the claim gets tested.

How High Occupancy Can Go

The question asked for an update on the 95%-plus cohort and for management's view of structural vacancy, with total-portfolio occupancy still at 88.3%. The answer refused a ceiling and framed the gap as a mix effect of buying low-occupancy assets.

Q: "I know historically, we have talked about the 95%-plus-occupied cohort. I guess I was curious if, number 1, we could get an update on those. And No. 2, if you had a view of what the structural vacancy of the portfolio is."
— Ronald Kamdem, Morgan Stanley

A: "We believe that, you know, we have a fairly significant number of. Or percent of our portfolio is above 90% occupied, and we believe there is no reason we cannot take the whole portfolio up there if we freeze the portfolio where it is today."
— Shankh Mitra, Chief Executive Officer

Assessment: A strong claim with a convenient condition attached: the portfolio is never frozen. The cohort follow-up was answered for the 90%-plus group (RevPOR above 6%, NOI above 21%) rather than the 95%-plus group the question named. The composition of the remaining third below 90% is still not disclosed, and that remains our open request.

What Constrains the Compounding

The dominant strategic line of questioning: at $21 billion of activity a year and with capital no longer scarce, what limits per-share growth over five years, and does size eventually work against the company? Management's answer was the same to both versions of the question. The constraint is opportunity and execution on the existing portfolio, not capital, and the chief executive said he would be "completely fine" if the company never bought another asset.

Q: "So as you think about Welltower over the next 5 years, what ultimately becomes the binding constraint to compound your cash flow? You know, is it acquisitions? Is it operating partner capacity? WBS?"
— Michael Goldsmith, UBS

A: "Acquisition-- first, is we are not capital constrained, we are opportunity-constrained. If we are not opportunity constrained, we would not be this selective."
— Shankh Mitra, Chief Executive Officer

Assessment: The right answer for a business whose returns come from what happens after closing, and the same-store numbers support it. It sits uneasily beside a quarter in which $3.1 billion of equity and units were issued to fund purchases, and a year in which 42% of guided per-share growth comes from investment activity. Both can be true; the second is the part the share count pays for.

Whether the Spread Holds at 95%

A model-relevant question: as RevPOR becomes the driver at low- to mid-90s occupancy, does the gap between unit revenue and unit cost hold? The answer used the 95%-plus cohort as the evidence and put its size at about a third of the same-store properties. In April management had described roughly half the portfolio as 95%-plus occupied, on a base it did not specify, so the two figures cannot be compared.

Q: "Guess I am just trying to understand if the spread between RevPOR and ExpPOR, does that hold steady as you start to push RevPOR more aggressively when it kind of gets up into that low- to mid-90% range?"
— Michael Carroll, RBC Capital Markets

A: "Now it is about 35% of our total properties in the same store pool. It just gives us a good view into how assets will perform or how more the portfolio performs as it hits that level. And we are seeing RevPOR, ExpPOR spreads there that are comparable to, if not greater than, what we see in the rest of the portfolio."
— Tim McHugh, Chief Financial Officer

Assessment: The best answer of the call for anyone modelling the margin. A cohort that is a third of the same-store pool and holds its spread at 95%-plus is direct evidence that margin expansion does not stop when occupancy does. It supports a terminal margin above a straight-line extrapolation, which is the main reason our FY2027 framework sits above the summer consensus.

The Capital-Light Businesses

The question asked how the fund and data-licensing businesses should grow over two to three years. The answer pointed to the new supplement disclosure, said revenue should keep rising, and reported a second equity fund in the market and licensing talks with many counterparties.

Q: "Just wondering if you could talk a little bit about the growth opportunities in your other asset light fee income driven businesses, specifically the funds business and licensing of the data."
— Omotayo Okusanya, Deutsche Bank

A: "We have had an incredible start to our fund management business. I think I previously described the full deployment of our first equity fund, the raising of a credit fund, that is going well."
— Nikhil Chaudhri, Chief Investment Officer

Assessment: For the first time the answer could point to a number, and it did. The number is small and the growth language is qualitative. A second equity fund would add fee-bearing capital, but even a doubling would leave the business a rounding error against $4.9 billion of normalized FFO for several years.

Whether Rates Have Repriced the Deal Market

The question asked where seniors housing values have repriced since rates moved up over the summer, across the three countries. The answer said it is too early to see it in prices and that the change so far is in seller behaviour: certainty of close is now worth more than headline price.

Q: "Where have you seen the most repricing in recent months? And can you just give us some sense for the magnitude of repricing that is occurring relative to, call it, 3 or so months ago before rates ran up a bit?"
— Michael Stroyeck, Green Street

A: "I think, it is probably too soon to see significant repricing. there is always a lag between you know, what you see on the Bloomberg screen versus what you see in a transaction market."
— Nikhil Chaudhri, Chief Investment Officer

Assessment: An honest answer that cuts against the company's near-term interest. If private values lag public rates, the 5.3% going-in yield of the third quarter was struck before the repricing, and the better buying should come in 2027. It also means the public equity has repriced first, which is part of why we can buy it more cheaply today.

Whether New Supply Arrives at the Top End

The bear question on pricing power: if development only works at the luxury end, will new supply land exactly where Welltower prices? The answer used development economics to say new building does not pencil today, and in passing gave the company's view of what its own acquisitions earn once improved.

Q: "But you have also said that development really only pencils at the high end. And I know there is, you know, virtually, you know, a very limited amount of new starts today, but any concern that when supply ramps that it will be at that higher end and luxury side of the business and limit your ability to push rate?"
— Austin Wurschmidt, KeyBanc Capital Markets

A: "the best development pitch that somebody has given me at the NIC conference was 7.5% on revenue. I will tell you that in our books is a negative development spread. We can do untrended acquisitions today, that is in the high-7% to low-8% range."
— Shankh Mitra, Chief Executive Officer

Assessment: Persuasive on supply in the near term and revealing on returns: management underwrites its purchases to a high-7% to low-8% yield after improvement, against a 5.3% going-in yield on the quarter's deals. That gap is the whole post-closing thesis in two numbers. The longer-run answer, that supply in the best locations takes a decade to permit, is plausible and untestable today.

What They're NOT Saying

1. The NAREIT guidance cut. NAREIT FFO guidance fell $0.15 to a $6.10 midpoint, below the $6.17 it started the year at. The guidance walk on the call covered normalized FFO only, and the word NAREIT did not appear in the call.
2. The HC-One restructuring and its cost. The release names it as a driver of $124.7M of other expenses. The quarterly filing says management of 89 of 282 homes has moved to other operators. The call did not mention it, and no analyst asked.
3. The U.K. competition undertakings. A finding of possible reduced competition in 30 local areas and a provisionally accepted sale of ten homes were not referenced. This is the third consecutive quarter without a management comment on U.K. or Canadian regulation.
4. Fourth-quarter normalizers at zero. Full-year guidance of $298M equals the $298.3M already booked. That assumes no transaction or legal costs on $7.7 billion of closings across 50 transactions, after $124.7M of other expenses in Q3 alone.
5. How fast the equity is being sold. About $2.64 billion of the new $7.5 billion programme was used in roughly two months, and 1.62 million more shares were sold in October. The call described "$3.1 billion from share issuance and OP unit funding" and nothing more.
6. The narrowing discount to replacement cost. Ten to fifteen percent this quarter against roughly twenty percent in July, on a 5.3% going-in yield. Neither change was discussed.
7. Losses in unconsolidated investments. Loss from unconsolidated entities rose to $30.7M from $12.6M, and $37.3M of normalizers relate to noncontrolling interests and unconsolidated entities, mostly book-value liquidation adjustments on in-substance real estate investments. These are excluded from normalized FFO with one footnote of explanation.
8. The composition of the below-90% third. The 90%-plus cohort was characterized again. The other third of the portfolio was not, for the third quarter running.
9. Flat sequential RevPOR. Same-store RevPOR was $6,066 against $6,074 in Q2 on the same pool, in the quarter management described as the best pricing environment in eleven years.

Market Reaction

• Pre-print setup: WELL closed at $240.61 on October 26, up 29.6% year to date against 12.1% for the S&P 500, up 35.2% over twelve months and 4.0% over the trailing thirty days. The fifty-two-week closing range entering the print was $176.06 to $252.07, so the stock came in about 4.5% below its record close.
• Overnight: after-hours and pre-market indications conflicted across sources. The regular session opened 3.0% lower at $233.28.
• Reaction session (October 27): the stock traded between $224.73 and $237.93 and closed at $226.72, down 5.8% or $13.89, on 6.0 million shares against a thirty-day average of 2.6 million, or 2.3 times normal. The S&P 500 rose 0.6%.
• Peers, same session: Ventas fell 4.7%, American Healthcare REIT 4.6% and Brookdale 2.4%.
• Second session (October 28): the stock opened at $222.81, touched $217.72, 9.5% below the pre-print close, and recovered to close at $227.20, up 0.2%, on 5.7 million shares. Ventas fell a further 2.7%.

Rates reach the premium multiple. This is the third consecutive quarter in which Welltower has beaten and raised and closed lower: down 1.0% in April and 1.9% in July after touching new highs, and down 5.8% this time without one. What changed is that the group moved with it. Two healthcare REIT peers with large seniors housing operating portfolios fell nearly as much on the same day, against a rising broad market. The company-specific part of the move is roughly a point. The rest is a sector being repriced for a rate path that management itself described, in detail, on the call.

The headline problem. The first stories led with a GAAP miss and, for readers of the reconciliation, a lower NAREIT guide. Neither is a surprise to anyone who has followed the normalizer gap, but both landed on a stock that entered the print up almost 30% for the year and within 5% of its record. In that setup a quarter that is excellent in the operating detail and messier in the headline line is sold first and read later. The second session's intraday low and recovery look like that reading taking place.

The reverse of the summer. From April to July the stock rose 14.8% while the normalized guide rose 1.9%, and we wrote that the multiple had done all the work. From July to October the stock fell 6.7% while the normalized guide rose 1.6%. The business kept compounding through both periods; the multiple gave back about three of the four-plus turns it had added. That symmetry is the core of today's rating change.

Street Perspective

Debate: Are Transaction Costs a Cost of Doing Business?

Bull view: the constructive argument is that excluding non-capitalizable deal and legal costs is standard REIT practice, that the costs buy assets which earn high-7% to low-8% once improved, and that NAREIT FFO per share still grew 18.3% this quarter. On either measure the business is compounding faster than almost anything in real estate.

Bear view: the skeptical reading is that a company doing 196 transactions a year incurs transaction costs every year, that other expenses have totalled $368.6M over four quarters, and that every cent of 2026's guidance increase has come from excluding them. Valuing the stock on a measure that removes a recurring cost of its central strategy flatters earnings by roughly $0.50 a share a year.

Our take: the bears have the better of the accounting argument and the bulls have the better of the economic one. We treat the excluded costs as real, which is why we lead our valuation with both measures and why earnings quality is now Materializing in our framework. But an 18% NAREIT grower at 37x NAREIT guidance is not the same proposition as a 25% grower at 35x normalized, and the stronger number is still strong.

Debate: Does Pricing Power Replace Occupancy as the Growth Engine?

Bull view: the argument gaining traction is that the handoff is happening early and with better economics than the occupancy story it replaces. RevPOR has accelerated three quarters running, the 90%-plus cohort is pricing above 6%, flow-through is at a post-COVID high, and new supply does not pencil.

Bear view: the counter is that pricing is the harder story to forecast and the more cyclical one. Residents fund moves partly from home equity, rates are rising, and the street-rate acceleration management describes is not yet visible in a sequential RevPOR series that was flat this quarter.

Our take: we lean bull on the evidence available, because the 95%-plus cohort already shows the spread holding at the occupancy levels where the bear case says it should fail. The decisive data point is the January rent cycle, which will show whether higher street rates have reset the base. We have added a RevPOR floor to our downgrade triggers so that the test has a consequence.

Debate: Do Higher Rates Help or Hurt the Acquisition Machine?

Bull view: the constructive case is that a refinancing wall of $10-12 billion a year in 2027 and 2028 will force sellers to choose certainty over price, and that a buyer with an A- balance sheet and an operating partnership currency sellers want to hold is the natural winner.

Bear view: the bear camp contends that the same rates compress the spread that makes the machine work. The equity's normalized FFO yield has risen to 2.9% while the going-in yield fell to 5.3%, the stock is the funding currency, and 20% of debt floats.

Our take: on balance, higher rates help Welltower relative to its competitors and hurt it in absolute terms. The deal flow is real, but the company will be buying with a cheaper currency than it had in July. Our upgrade does not depend on the acquisition engine accelerating; it depends on the existing portfolio's pricing, which the rate path affects far less.

Debate: Is 35x a Reset or a Waypoint?

Bull view: a growing consensus view is that the sell-off was sector beta on a company that keeps raising guidance, and that at about 30x a reasonable FY2027 estimate the stock is back to where long-duration compounders usually trade.

Bear view: the counter is that REIT multiples have only started to adjust to a 5%-plus ten-year yield, that 35x current-year normalized FFO is still the top of the sector, and that the next leg of compression could easily take another two or three turns.

Our take: we think 35x is closer to a reset than a waypoint for this business, because the earnings power behind the multiple rose while the price fell. Our fair value applies 32-35x to FY2027 against 30.5x today on the same year, so it does assume a partial recovery, to about the July multiple. That is the part of the case most exposed to rates, and we name it as such.

Model Framework & Valuation

Valuation at the October 28 Close

At $227.20 against 754.9 million average diluted shares, the equity is capitalized at approximately $171.5 billion.

Fair Value and Sensitivity

We set a 12-month fair value of $240-$260, or 32-35x our FY2027 normalized FFO midpoint of $7.45. The midpoint of $250 is 10.0% above the October 28 close, or about 11.5% including the dividend. On the same FY2027 estimate the stock trades at 30.5x today, so the range assumes the multiple recovers to 32-35x. On FY2026 the range is about 37-40x against 35.0x today. Put plainly: the fair value assumes the multiple returns to about where it stood in July, on higher earnings. That recovery is not assured while rates rise, and the 30x row below shows the result if it does not come.

We want to be explicit about one thing. The July price of $243.57 sits inside this range, at 32.7x the same FY2027 estimate. We rated it a Hold there, which is what a price at fair value earns. The upgrade does not come from rolling the valuation year forward: July's own 38x base-case multiple on today's $6.50 gives $247, inside the range. It comes from a 6.7% lower price against a normalized guide that rose 1.6%, a pricing trend that strengthened, and a trigger we published that fired.

In July's sensitivity table the 36x row, $230.40, was labelled "guide is met and modestly beaten, multiple gives back a turn." The guide was met and beaten, and the stock now sits below that row, at a multiple three turns lower.

Thesis Scorecard Post-Earnings

Overall: the thesis strengthened on the operating business and on the price, and weakened on earnings quality. Both operating pillars improved: the pricing handoff arrived early and margins rose with it. The earnings-quality concern we have carried since initiation became the clearest it has been, with the whole of 2026's guidance increase coming from excluded costs. The valuation concern eased by three turns of multiple. Two status tags moved: Bear-1 from Materializing to Emerging and Bear-2 from Emerging to Materializing.

Action: Upgrading to Outperform from Hold, 12-month fair value $240-$260. In July we listed three things that would make us buyers and wrote that any one of them would do it. One arrived in full, a second arrived about half the way, and the downgrade trigger aimed at the normalizer gap did not fire because its valuation condition was not met. We are honouring that framework. Conviction is lower than the operating results alone would justify, because the reason for our caution is still live: the stock is valued on a measure that now excludes about $0.40 a share of 2026 costs. We keep all three July downgrade triggers as written. With the gap condition already met, the first now fires on the multiple alone: a return above 38x FY2026E normalized FFO, about $247, without an estimate increase. That price sits inside our fair value range, so if it fires it nets against this upgrade and returns us to Hold, and we state that now rather than after the fact. We add two downgrade triggers, both outside our base case: SHO same-store RevPOR growth below 4.0% for two consecutive quarters, which would mean the pricing handoff has failed; and fourth-quarter net normalizing items of $0.25 a share or more, a second straight quarter at Q3's level against a guide of zero. Disclosure of the below-90% cohort would raise our conviction, not our rating.